

CorNotes

CVI SEMINAR SERIES

The next CVI seminar will be held on **Thursday, March 16, 2006 at 4:00 pm** in **The Van Kampen Conference Center, Building 110, Room 6274**. Our speaker is:

Irwin Klein, M.D.
Associate Chairman of Medicine
North Shore University Hospital
Professor of Medicine and Cell Biology
NYU School of Medicine
Manhassat, NY

The title Dr. Klein's talk is:

"Molecular Basis for the Use of Thyroid Hormone in the Treatment of Chronic Congestive Heart Failure"

For further information about the CVI Seminar Series, contact Dr. Leanne Cribbs at x72817.

CVI JOURNAL CLUB

March 9.....Ms. Hoefling
 March 23.....Dr. Byron

For further information, contact Dr. Ken Byron at x72819.

RECENT PUBLICATIONS FROM THE CVI

Dieter RS, Schmidt WT, Pacanowski JP, Jaff MR. Renovascular hypertension. *Exp Rev Cardiovasc Ther.* 3:413-422, 2005.

Goodfellow RJ, Schwartz J, Leya F. Black aorta: a rare finding at aortic valve replacement. *J Invasive Cardiol.* 17(3):165-167, 2005.

Hursting MJ, Lewis BE, MacFarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. *Clin Appl Thromb Hemost.* 11(3):279-287, 2005.

Ramana R, Arab D, Joyal D, Steen LH, Cho L, Lewis BE, Liu J, Loeb H, Leya FS. Coronary perforation in the new interventional era. *J Invasive Cardiol.*17(11):603-605, 2005.

Pamboukian SV, Costanzo MR, Dunlap S, Rayburn B, Westfall AO, You ZY, Hung E, McLeod M, Heroux A. Relationship between bridging with ventricular assist device on rejection after heart transplantation. *J Heart and Lung Transplant.* 24:310-315, 2005.

Tambur AR, Pamboukian SV, Costanzo MR, Herrera ND, Dunlap S, Montpetit M, Heroux A. The presence of HLA-directed antibodies post heart transplantation is associated with poor allograft outcome. *Transplantation* 80(8):1019-1025, 2005.

Gudmundsson GS, Kahn SE, Moran JF. Association of mild transient elevation of troponin I levels with increased mortality and major cardiovascular events in the general patient population. *Arch Pathol Lab Med* 129:474-480, 2005.

Messmore HL, Jeske WP, Wehrmacher W, Coyne E, Mobarhan S, Cho L, Leya F, Moran JF. Antiplatelet Agents: Current Drugs and Future Trends. *Hematol Oncol Clin North Am.* 19:87-117, 2005.

Bossuyt, J., Ai, X., Moorman, J.R., Pogwizd, S.M., Bers, D.M. Expression and phosphorylation of the Na-pump regulatory subunit phospholemman in heart failure. *Circ. Res.* 97(6):558-565, 2005.

Shannon, T.R., Bers, D.M., Blatter, L.A., Niggli, E. Confocal imaging of CICR events from isolated and immobilized SR vesicles. *Cell Calcium* 38(5):497-505, 2005.

Haas, S., Wolf, H., Kakkar, A.K., Fareed, J., Encke, A. Prevention of fatal pulmonary embolism and mortality in surgical patients - A randomized double-blind comparison of LMWH with unfractionated heparin. *Thromb. Haemost.* 94(4):814-819, 2005.

Holinstat M, Roy A, Broman M, Samarel AM, Malik AB, Mehta D. Focal adhesion kinase activation restores endothelial barrier function by suppressing Rho activity. *J. Biol. Chem.*, 281: 2296-2305, 2006.

Roche Heart STN Clinical Trial

Dr. Alain Heroux of the section of Heart Failure/Transplant is the principal investigator conducting the Roche Heart STN clinical trial on behalf of Hoffmann-LaRoche, Inc.

The purpose of this study is to evaluate the overall efficacy and safety, including the effect on renal function, of sirolimus (Rapamune) replacing CNI in a standard care regimen of CNI, mycophenolate mofetil (MMF), and steroids in heart transplant patients.

The combination of cyclosporine and MMF and corticosteroids has been proven effective in helping to prevent the rejection of a patient's new heart. However, there is a possibility that the CNI part of this combination, after many years, can cause damage to the patient's kidneys. This damage can be irreversible and can lead to kidney failure requiring dialysis. In this study, the CNI part of the combination will be replaced by a different immunosuppressant, sirolimus. The purpose of the study will be to see if sirolimus has a better long-term effect in protecting the patient's kidneys, while at the same time doing an equally good job at preventing damage to the new heart.

For more information or to alert the Heart Failure/Transplant team of potential participants, please contact the project's coordinator, Melissa Hill, at 708-327-2723.

CARDIOLOGY - CVI RESEARCH DIVISION BASIC SCIENCE SEMINAR

The Cardiology Division and the CVI Research Division are sponsoring a series of joint seminars by Loyola Faculty. The following seminar is scheduled:

March 17.....Dr. Walter Jeske

The title of Dr. Jeske's talk is:

"Novel Targets for Antiplatelet Therapy"

The Seminar will be held at 12:00 pm in Building 110, Room 6291.

For further information, contact Dr. Samarel at x72821



Preparing People to Lead Extraordinary Lives

LOYOLA
UNIVERSITY
CHICAGO

Stritch School of Medicine